Proceedings of the 15th International Conference of Racing Analysts and Veterinarians, Dubai, United Arab Emirates

PRELIMINARY REPORT ON THE CONFIRMATION AND QUANTITATIVE DETERMINATION OF SALMETEROL IN EQUINE URINE

C. G. Hughes, A. F. Lehner, W. Karpiesiuk, F. C. Camargo, D. J. Harkins, W. E. Woods, J. Bosken, J. Boyles, A. Troppmann and T. Tobin

Department of Veterinary Science, The Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky 40546, USA

ABSTRACT

Salmeterol is a $ß_2$-adrenergic agonist and an Association of Racing Commissioners International (ARCI) Class 3 drug. Trade names of its xinafoate salt are Arial (Dompé), Salmetedur (Menarini) and Serevent (Glaxo). Salmeterol is used routinely to increase ease of breathing in race horses during their training. Due to its central nervous system stimulant and bronchodilator properties, its administration to a horse just prior to race time has the potential to affect the horse's performance. Therefore, a reliable method of analysis for this compound is necessary.

This paper investigates a method for the identification and quantitation of salmeterol in equine urine and serum using liquid-liquid extraction followed by liquid chromatography and tandem mass spectrometry (LC/MS/MS). Serum concentrations at 30 min were generally below the minimum level of quantitation. Urine salmeterol concentrations peaked at about 2 h post dose following administration of 500 µg both iv and intratracheally at concentrations of 14 ng/ml and 4 ng/ml, respectively. Urinary salmeterol was detectable for 6–8 h following dosing by either method.

INTRODUCTION

Salmeterol, (±)-4-Hydroxy-α1-[[[6-(4-phenylbutoxy) hexyl]amino]methyl]-1,3-benzenedimethanol (Fig 1) is a $ß_2$-adrenergic agonist and an Association of Racing Commissioners International (ARCI) Class 3 drug. In human medicine, salmeterol is used for conditions such as asthma and chronic obstructive pulmonary disease (Caverley *et al.* 2003; Coraux *et al.* 2003; Dal Negro *et al.* 2003; Lindqvist *et al.* 2003; Lyseng-Williamson and Plosker 2003; Reid *et al.* 2003; Zimmermann *et al.* 2003). $ß_2$-receptor agonists are commonly used to increase ease of breathing in racehorses during their training (Hendrikson and Rush 2001). Due to the central nervous system stimulant and bronchodilator properties of salmeterol, its administration to a horse just prior to race has the potential to affect performance and a reliable method of analysis for salmeterol is therefore necessary.

This paper investigates and describes a method for the identification and quantitation of salmeterol in equine urine and serum using liquid-liquid extraction followed by liquid chromatography and tandem mass spectromentry (LC-MS/MS).

Briefly, salmeterol-d_{12} xinafoate was synthesised for use as an internal standard. Salmeterol and its internal standard were extracted from alkaline urine or serum with dichloromethane. The extract was evaporated to dryness, redissolved in HPLC mobile phase and injected into a liquid chromatograph interfaced with a tandem mass spectrometer operating in the electrospray ionisation [positive] (ESI^+) mode. Ion fragmentation mechanisms specific for salmeterol and the internal standard salmeterol-d_{12} were monitored by MS/MS to identify and quantitate salmeterol.

In order to ensure that the analytical method possessed adequate sensitivity for use in the regulatory control of the use of this medication, samples from horses which had been administered salmeterol were analysed.



Fig 1: Salmeterol.

Fig 2: Salmeterol-d_{12} internal standard.

Materials and methods

Horses and sample collection

Two mature Thoroughbred mares weighing 542 and 572 kg were used for this study. The animals were maintained on grass hay and feed (12% protein), which was a 50:50 mixture of oats and an alfalfa-based protein pellet. Horses were fed twice a day. The animals were vaccinated annually for tetanus and de-wormed quarterly with ivermectin. A routine clinical examination was performed prior to each experiment to ensure that the animals were healthy and sound. During experimentation, horses were provided water and hay *ad libitum*. All animal care was in compliance with the guidelines issued by the Division of Laboratory Animal Resources and was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Kentucky.

Salmeterol (500 µg) was administered, as its xinafoate salt, both as a single iv injection in the right jugular vein and also a single intratracheal injection in a second horse. Blood samples were collected from the left jugular vein for analyses at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6 and 24 h into Vacutainer serum tubes (Becton Dickinson, New Jersey, USA), allowed to clot, then centrifuged at 900 x *g* for 15 min at 20°C. After separation, the serum samples were stored at -20°C until assayed. During the first day, complete urine collection was accomplished with a Foley catheter at 0, 1, 2, 3, 4, 5 and 6 h after administration. At 24 h after administration, a Harris flush tube (24 Fr x152.4 cm; Seamless, Florida, USA) was used to collect the urine samples. Urine was divided into appropriate aliquots and stored at -20°C until assayed.

After one week, the drug was again administered to each of the 2 horses by the alternative routes of administration. Serum and urine were again obtained in the same manner.

Synthesis of salmeterol standard and salmeterol-D_{12} internal standard

A certified salmeterol standard was not commercially available. We therefore elected to synthesise in-house both salmeterol and its deuterated analogue for use as standard and internal standard, respectively. Salmeterol xinafoate and salmeterol-d_{12} xinafoate were synthesised from methyl salicylate, 1,6-dibromohexane and its d_{12} analogue, and 4-phenyl-1-butanol. The final products (Figs 1 and 2) were obtained in high chemical and isotopic purity as their xinafoate salt (Karpiesiuk *et al.* 2005) .

Sample and calibrator preparation

All urine samples were subjected to ß-glucuronidase hydrolysis prior to extraction as described by Combie *et al.* (1982) and Lehner *et al.* (2005). Serum was processed without hydrolysis.

Methanol solutions of salmeterol and salmeterol-d_{12} were prepared. Using a micropipetor, calibrators in the range of 0–25 ng/ml were prepared by serial dilution and addition of a known quantity of salmeterol solution to 4 ml aliquots of blank urine or 2 ml of blank serum in a 15 ml test tube with a screw cap. Salmeterol-d_{12} was added to each tube to produce a concentration of 25 ng/ml. Identical quantities of internal standard were added to each 4 ml aliquot of unknown sample to be analysed.

Extraction procedure

Samples were made alkaline by addition of 200 µl of concentrated NH_4OH (Fisher). Dichloromethane (5 ml) was added and the tubes were capped and rotated on a rotorack (Fisher Model 346) for 15 min. The tubes were then centrifuged at 900 x *g* at room temperature to separate the layers. The top aqueous layer was aspirated to waste, and the remaining dichloromethane layer was carefully decanted into a test tube which was placed in a water bath (Zymark TurboVap LV) at 40°C while the solvent was evaporated to dryness under a stream of nitrogen.

TABLE 1: HP 1050 HPLC gradient timetable

Time	A%	B%
0.00	10.0	90.0
1.20	10.0	90.0
5.00	89.5	10.5
8.00	89.5	10.5
8.50	10.0	90.0
17.00	10.0	90.0

Mobile phase system:
A = acetonitrile + 0.05% formic acid
B = HPLC-grade water + 5% acetontirile + 0.05% formic acid.



Fig 3: Relationship between ion intensity and collision energy.

Instrumentation

A Hewlett-Packard 1050 Liquid Chromatograph interfaced with a Micromass (Massachusetts, USA) Quattro II tandem Mass Spectrometer with electrospray inlet was operated in the positive ion mode.

Chromatography

Chromatography was performed on a Phenomenex (California, USA) Luna phenyl/hexyl 30 mm x 1.0 mm x 3 micron phenyl-hexyl column with a flow of 0.150 ml/min. An acetonitrile-water-formic acid mobile phase gradient was used as described in Table 1. Re-dissolved extract (10 µl) was injected.

TABLE 2: Principal ions in product ion spectrum of salmeterol m/z 416 $[M+H]^+$ ion. 10 µg/ml salmeterol in 0.05% formic acid:ACN, 1:1, infused at 1.2 ml/h into the Quattro II ESI-MS/MS

Mass	% relative abundance	Mass	% relative abundance
416	9	189	7
398	52	151	9
380	100	135	14
270	5	98	10
248	13	91	17
232	56		

TABLE 3: Ion transitions monitored – MRM of 6 mass pairs (ESI+)

Channel	Parent	Daughter	Dwell	
1	416.20	398.20	0.02	salmeterol
2	416.20	380.20	0.02	
3	416.20	248.20	0.02	
4	416.20	232.00	0.02	
5	428.20	410.20	0.02	salmeterol-d_{12}
6	428.20	392.20	0.02	

Mass spectrometry

Mass spectrometric parameters for data acquisition were determined by obtaining a product ion spectrum for infused salmeterol, then choosing specific ion transitions and optimising parameters for most sensitive monitoring. Fragments of interest arising from the molecular ion m/z 416 include the m/z 398, 380, 248, 232 and 91 ions (Tables 2 and 3).

Optimal tuning parameters for detection of salmeterol were determined during direct infusion



Fig 4: Product ion spectra at different collision energies. Salmeterol product ion spectra at low (top; CE=20) and high (bottom; CE=40) collision energy settings. Salmeterol [10 µg/ml in 0.05% formic acid: acetonitrile, 1:1] was examined by direct infusion into the ESI(+)-MS/MS at 1.2 ml/hr. Peak labels indicate m/z value [top value] and intensity [bottom value].



Fig 5: Salmeterol fragmentation. The figure shows the assigned origins of fragments m/z 91 [benzyl group] and 232 [phenylbutyl-O-hexyl ether fragment].

of 10 μg/ml salmeterol in 0.05% formic acid (aq):acetonitrile, 1:1.

Spectrometry involved MRM monitoring of 4 diagnostic ion transitions arising by fragmentation of the salmeterol m/z 416 $[M+H]^+$ ion, and 2 ion transitions from the internal standard as shown in Table 3. The ion transitions used for quantitation were m/z 416>398 for salmeterol and m/z 428>410 for the internal standard.

Results

Dynamic mass calibration of salmeterol precursor ion values in 0.1 amu increments determined that the optimal signal for m/z 398 in the m/z 416-417 range occurred at m/z 416.2, providing at least 5% improvement over nominal mass 416 (data not shown). Best yield also occurred at m/z 398.2.

Product ion abundances were measured at increasing collision energies to determine maximum output intensity, as shown in Figure 3. Ion m/z 91 generally provided the best response, but was considered less specific than the dehydration product at m/z 398; the second dehydration product m/z 380 generally parallels that of m/z 398. Low collision energy settings were therefore preferred for m/z 398 and 380, retaining fairly strong signal at the additional m/z 232 qualifier. Figure 4 contrasts the full product ion spectra at low and high collision energies; note the general lack of peaks at the higher setting, despite the intense m/z 91. Figure 5 shows the structural origins assigned to fragments m/z 91 and 232.

Liquid/liquid extraction was investigated for 3 organic solvents, [ethyl acetate (EA), dichloromethane (DCM) and petroleum ether (pet ether)]. DCM and EA yielded partition coefficients greater than 95% with ammonia-basified water. DCM was deemed the best choice of solvent because it formed less emulsion during the serum and urine extraction process.

Isocratic HPLC based on conditions similar to those developed for clenbuterol (Lehner *et al.* 2001) yielded a low retention time peak for salmeterol when optimised to a mobile phase flow rate of 0.150 ml/min on the 1 mm id Phenomenex Luna phenyl-hexyl column. Injection of 10–300 ng on column (equivalent to injection of 100% of the extract of 1 ml in the 10–300 ng/ml sample range) resulted in a linear response with some curvilinearity above 200 ng, probably owing to the relatively low loading capacity of the column. Injection of 20 pg, 200 pg, 2 ng and 20 ng on column revealed linearity of the method over a 4 log-unit span. A gradient HPLC method described in the methods section was then developed for the same column at 0.15 ml/min which retained the sensitivities described. Salmeterol was eluted in a sharp non-tailing peak at about 9 min under these conditions (Fig 6). The right portion of Figure 6 displays nested fragment ion peaks at the low collision energy used for quantitative purposes.

Salmeterol calibration curves prepared from extracted standards were curvilinear between



Fig 6: Salmeterol total ion chromatograms. Gradient HPLC of 2.5 ng/ml salmeterol standard extracted from urine; detection is with ESI(+)-MS/MS. The left panel shows total ion chromatogram (TIC) on a 1 mm bore 3μ phenyl-hexyl column (Phenomenex Luna), right shows the array of nested fragment ion peaks at a collision energy of 16.



Fig 7: Typical salmeterol standard curve generated by Masslynx 3.4 software. Coefficient of determination $r^2 = 0.998$.

0.025 and 50 ng/ml with a coefficient of determination $r^2 > 0.99$. Figure 7 is a typical standard curve. Over the lower concentration range of 0.025 to 2.5 ng ml the standard curve was linear with a first-order regression plot having a coefficient of determination $r^2 > 0.99$. The lower limit of detection in urine for this method was 0.025 ng/ml while the lower limit of quantitation was estimated at about 0.125 ng/ml.

Salmeterol (500 µg) was administered to 2 horses, one via the iv route and one the intratracheal (IT) route. One week later, each horse was again dosed using the opposite route. Urinary salmeterol concentrations were found to reach peak values at about 2 h following either route of administration. As shown in Table 4, iv administration gave an average maximum urinary concentration of about 14 ng/ml, while intratracheal administration gave a maximum concentration of about 4 ng/ml. Urinary salmeterol concentrations remained above the limit of quantitation for at least 6–8 h post dose for both routes of administration.

Serum salmeterol concentrations following iv administration of 500 µg salmeterol peaked at an average value of approximately 0.17 ng/ml at 15 min post dose and declined to about 0.08 ng/ml by 30 min. This 15 min value is approximately equivalent to our measured lower limit of quantitation in serum, suggesting that this method, using our instrumentation, has insufficient sensitivity for routine analysis of serum for salmeterol.

Discussion

Due to low doses of salmeterol used in the horse, low concentrations of target analyte are found in serum and urine of the horse. Maximum extraction efficiency and adjustment of instrumental parameters to achieve maximum sensitivity and thus, the lowest possible detection limit, were attempted in an effort to measure these low concentrations. While salmeterol is generally administered to horses as an aerosol, we chose iv and IT administration for this preliminary study in order to accurately quantify the dose, that being the most important parameter in any pharmacokinetic calculations we might make.

Extraction of salmeterol by direct application of the clenbuterol SPE method (Lehner *et al.* 2001) yielded poor salmeterol recovery. A single step solvent extraction with dichloromethane resulted in salmeterol extraction efficiencies greater than 90% with both serum and urine.

Although clenbuterol was used by Van Eenoo *et al.* (2002) for an internal standard, we chose not to use it due to the following potential disadvantages: significant difference in the HPLC retention times of clenbuterol and salmeterol may contribute to assay variability; somewhat dissimilar chemical classes produce moderate differences in extractability which can produce

TABLE 4: Concentration (ng/ml) of salmeterol in urine following a dose of 500 µg administed both iv and intratracheally (IT)

Hour	Horse B-77 IT	Horse B-41 IT	Horse B-77 IV	Horse B-41 IV
0	**	**	**	**
1	1.6	0.7	15.0	5.37
2	5.0	3.0	10.5	13.0
4	2.7	1.8	4.4	4.6
6	1.7	1.7	4.9	2.0
8	1.5	1.3	3.9	2.8
24	0.26	0.1*	1.1	**
48	0.1*	**	0.4	**

* Below limit of quantitation
** Below limit of detection

variability in quantitative results; no real advantage is provided by clenbuterol in terms of blocking non-specific sites to which salmeterol itself might bind during extraction, even with use of silanised glassware. Synthesis and use of a deuterated salmeterol internal standard (Fig 2) eliminated these potential problems.

The lower limit of detection in urine of 0.025 ng/ml and the lower limit of quantitation of about 0.125 ng/ml is similar to that obtained by Van Eenoo *et al.* (2002) who used different instrumentation. Recent advances in mass spectrometry and chromatography, such as the Quattro Z-spray inlet and micro-bore capillary columns, may have the potential to significantly lower these limits of detection and quantitation.

In summary, we have developed a LC/MS/MS method for the analysis of salmeterol in the horse. While we were unable to achieve adequate sensitivity for the analysis of the low concentrations of salmeterol found in serum, we were able to identify and quantitate urinary salmeterol for at least 6–8 h following doses of 500 µg of salmeterol administered both iv and intratracheally.

Acknowledgements

Publication # 340 from the Equine Pharmacology, Experimental Therapeutics and Toxicology Program at the Maxwell H. Gluck Equine Research Center and the Department of Veterinary Science, University of Kentucky.

Published as Kentucky Agricultural Experiment Station Article 04-14-09 with approval of the Dean and Director, College of Agriculture and Kentucky Agricultural Experiment Station.

The data presented in this paper, in part, also appeared in Chromatographia Supplement (2004) Vol 59, pp S79-S84.

References

Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J. and Maden, C. (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* **361,** 449-456.

Combie, J., Blake, J.W., Nugent, T.E. and Tobin, T. (1982) Morphine glucuronide hydrolysis: Superiority of ß-glucuronidase from *Patella vulgata*. *Clin. Chem.* **28,** 83-86.

Coraux, C., Kileztky, C., Polette, M., Hinnrasky, J., Zahm, J.M., Devillier, P., De Bentmann, S. and Puchelle, E. (2003) Airway epithelial integrity is protected by a long-acting beta2-adrenergic receptor agonist. *Am. J. Respir. Cell Mol. Biol.* Oct 3 [Epub ahead of print].

Dal Negro, R.W., Pomari, C., Tognella, S. and Micheletto, C. (2003) Salmeterol and fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. *Pulm. Pharmacol. Ther.* **16,** 241-246.

Henrikson, S.L. and Rush, B.R. (2001) Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction. *J. Am. vet. med. Ass.* **218,** 1961-1965.

Karpiesiuk, W., Lehner, A. and Tobin, T. (2005) Synthesis and certification of salmeterol and salmeterol-d_{12} standards. *Proc. 15th int. Conf. racing Anal. Vet.* Eds: P.H. Albert, T. Morton and J.F. Wade. R&W Communications, Newmarket, pp 405.

Lehner, A.F., Harkins, J.D., Karpiesiuk, W., Woods, W.E., Robinson, N.E., Dirikolu, L., Fisher, M. and Tobin, T. (2001) Clenbuterol in the horse: confirmation and quantitation of serum clenbuterol by LC-MS-MS after oral and intratracheal administration. *J. anal. Toxicol.* **25,** 280-287.

Lehner, A.F., Hughes, C.G., Harkins, J.D., Nickerson, C., Mollett, B., Dirikolu, L., Bosken, J.M., Camargo, F., Boyles, J., Troppmann, A., Karpiesiuk, W., Woods, W.E. and Tobin, T. (2005) Detection and confirmation of ractopamine and its metabolites in horse urine after Paylean(R) administration. *J. anal. Tox.* In press.

Lindqvist, A., Karjalainen, E.M., Laitinen, L.A., Kava, T., Altraja, A., Pulkkinen, M., Halme, M. and Laitinen, A. (2003) Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. *J. Allergy Clin. Immunol.* **112,** 23-28.

Lyseng-Williamson, K.A. and Plosker, G.L. (2003) Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. *Pharmacoeconomics* **21,** 951-989.

Reid, D.W., Ward, C., Wang, N., Zheng, L., Bish, R., Orsida, B. and Walters, E.H. (2003) Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma *in vivo*. *Eur. Respir. J.* **21,** 994-999.

Van Eenoo, P., Deventer, K. and Delbeke, F.T. (2002) Quantitative detection of salmeterol after inhalation in equine urine by liquid chromatogrpahy/tandem mass spectrometry. *Rapid Commun. Mass Spec.* **16,** 1755-1759.

Zimmermann, T., Gulyas, A., Bauer, C.P., Steinkamp, G. and Trautmann, M. (2003) Salmeterol versus sodium cromoglycate for the protection of exercise induced asthma in children--a randomised cross-over study. *Eur. J. med. Res.* **8,** 428-434.